Kailera Therapeutics (NASDAQ:KLRA) Reaches New 12-Month Low – Here’s Why

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) reached a new 52-week low during mid-day trading on Saturday . The company traded as low as $18.85 and last traded at $19.37, with a volume of 450718 shares trading hands. The stock had previously closed at $20.99.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. William Blair assumed coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating on the stock. Wall Street Zen lowered shares of Kailera Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Jefferies Financial Group assumed coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set a “buy” rating and a $48.00 price target on the stock. Zacks Research upgraded shares of Kailera Therapeutics to a “hold” rating in a report on Wednesday, May 13th. Finally, TD Cowen assumed coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set a “buy” rating and a $57.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $42.75.

Kailera Therapeutics Trading Down 7.7%

Insider Activity at Kailera Therapeutics

In related news, major shareholder Rtw Investments, Lp acquired 500,000 shares of the stock in a transaction that occurred on Monday, April 20th. The shares were purchased at an average cost of $16.00 per share, with a total value of $8,000,000.00. Following the completion of the transaction, the insider owned 10,776,820 shares of the company’s stock, valued at approximately $172,429,120. This trade represents a 4.87% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Andrew T. Kaplan acquired 8,398,438 shares of the stock in a transaction that occurred on Monday, April 20th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $134,375,008.00. Following the completion of the transaction, the director directly owned 26,255,581 shares of the company’s stock, valued at $420,089,296. This represents a 47.03% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have purchased 10,460,938 shares of company stock valued at $167,375,008.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.